Endogenous adenine production was blocked with a specific small-molecule inhibitor of MTAP (MTDIA) and found to protect against diabetic renal hypertrophy and elevation of kidney KIM1 and was protective of decline in kidney function, as measured by serum cystatin C. It is possible that chronic MTAP inhibition with MTDIA could be developed as a safe therapeutic, as a prior study found that MTDIA extended life span in mice with colon cancer, and it was provided for 294 days without evidence of toxicity (32). This evidence concerns the gene HAVCR1 and malignant colon neoplasm.